NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Yimei? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
64%
Finnrick rating
#394 of 500 ranked vendors
107 of 130 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Yimei's purity-focus record is strongest in GHK-Cu and Ipamorelin, with Retatrutide improving after earlier identity, purity, and fill volatility. Weaker signals cluster in TB-500, CJC-1295, and NAD+, and confidence is tempered by dispersed results, recurring missing batch IDs, and heavier evidence in only a few peptides.

methodology →
vendor intelligence report
Vendor Intelligence Report: Yimei

Corporate filings trace dissolved UK Yimei entities, while the live Pepturion stores publish no clear legal seller. The report follows COA attribution gaps, Wise/Shopify payment rails, Peptaura continuity records and discount-code promotion trails.

35 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.10
94%
18
2
Retatrutide
$1.28
84%
53
3
Ipamorelin
$1.14
81%
8
4
Tirzepatide
$0.56
80%
7
5
hCG
$0.60
64%
4
6
BPC-157
$1.00
58%
12
7
Tesamorelin
$3.69
57%
6
8
TB-500
$2.00
47%
7
9
CJC-1295
$2.58
46%
7
10
Epithalon
$0.48
40%
3
11
MOTS-c
$0.71
38%
3
12
NAD+
$0.02
30%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%6 Mar 2026: 70%6 Mar 2026: 71%6 Mar 2026: 71%6 Mar 2026: 71%7 Mar 2026: 71%7 Mar 2026: 72%7 Mar 2026: 72%10 Mar 2026: 67%10 Mar 2026: 68%18 Mar 2026: 67%18 Mar 2026: 68%19 Mar 2026: 68%21 Mar 2026: 67%23 Apr 2026: 68%23 Apr 2026: 67%28 Apr 2026: 66%28 Apr 2026: 66%28 Apr 2026: 66%28 Apr 2026: 66%28 Apr 2026: 66%28 Apr 2026: 66%28 Apr 2026: 67%30 Apr 2026: 67%30 Apr 2026: 67%30 Apr 2026: 67%6 May 2026: 68%19 May 2026: 68%20 May 2026: 70%16 Jun 2026: 70%17 Jun 2026: 70%10 Jul 2026: 70%16 Aug 2026: 70%21 Aug 2026: 70%21 Aug 2026: 70%21 Aug 2026: 70%21 Aug 2026: 70%25 Sep 2026: 66%25 Sep 2026: 64%14 Oct 2026: 64%20 Oct 2026: 64%17 Nov 2026: current 64%70%70%64%Mar 26Nov 26
Peptide testing

Ordered peptides from Yimei? Mail in a sample (US only) and let us test it.

Test my supply
Yimei test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
20 Oct 2026
Pass
GHK-Cu
lab nameView COA
14 Oct 2026
Pass
Retatrutide
lab nameView COA
25 Sep 2026
Pass
hCG
lab nameView COA
25 Sep 2026
Fail
NAD+
lab nameView COA
21 Aug 2026
Pass
GHK-Cu
lab nameView COA
21 Aug 2026
Pass
TB-500
lab nameView COA
21 Aug 2026
Fail
BPC-157
lab nameView COA
21 Aug 2026
Pass
Epithalon
lab nameView COA
20 Aug 2026
Incomplete
TB-500
lab nameView COA
16 Aug 2026
Pass
Retatrutide
lab nameView COA
1-10 of 132

About Yimei test results from Finnrick

Yimei is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 132 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Yimei peptides in this dataset are CJC-1295 (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 132 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Yimei? Mail in a sample (US only) and let us test it.

Test my supply